^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | fimepinostat (CUDC-907) (PI3K inhibitor, HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells
Published date:
01/04/2020
Excerpt:
Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation. Lastly, CUDC-907 treatment also inhibited the growth of Ba/F3 ponatinib-resistant cells, K562 nilotinib-resistant cells, and T315I mutant primary samples.
DOI:
10.1007/s00280-019-04022-x
